{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T05:56:51Z","timestamp":1793858211161,"version":"4.6.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"BRIDGE","award":["2022-ID 27321"],"award-info":[{"award-number":["2022-ID 27321"]}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell'Istruzione, dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["2022LSFKWE"],"award-info":[{"award-number":["2022LSFKWE"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell'Istruzione, dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["2023-2027 14586 DIORAMA"],"award-info":[{"award-number":["2023-2027 14586 DIORAMA"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell'Istruzione, dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["PNC0000001"],"award-info":[{"award-number":["PNC0000001"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell'Istruzione, dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["2023-2027 14586"],"award-info":[{"award-number":["2023-2027 14586"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031478","name":"EC | NextGenerationEU","doi-asserted-by":"publisher","award":["P2022E3BTH"],"award-info":[{"award-number":["P2022E3BTH"]}],"id":[{"id":"10.13039\/100031478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019180","name":"EC | Horizon Europe | Excellent Science | HORIZON EUROPE European Research Council","doi-asserted-by":"publisher","award":["101020342"],"award-info":[{"award-number":["101020342"]}],"id":[{"id":"10.13039\/100019180","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020581","name":"Fondazione AIRC per la ricerca sul cancro ETS","doi-asserted-by":"publisher","award":["21091"],"award-info":[{"award-number":["21091"]}],"id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020581","name":"Fondazione AIRC per la ricerca sul cancro ETS","doi-asserted-by":"publisher","award":["28922"],"award-info":[{"award-number":["28922"]}],"id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020581","name":"Fondazione AIRC per la ricerca sul cancro ETS","doi-asserted-by":"publisher","award":["29286"],"award-info":[{"award-number":["29286"]}],"id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020581","name":"Fondazione AIRC per la ricerca sul cancro ETS","doi-asserted-by":"publisher","award":["27321"],"award-info":[{"award-number":["27321"]}],"id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["FPRC 5x1000 Ministero della Salute 2022 CARESS"],"award-info":[{"award-number":["FPRC 5x1000 Ministero della Salute 2022 CARESS"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["Ricerca Corrente 2026 to the Candiolo Cancer Institute,FPO-IRCCS"],"award-info":[{"award-number":["Ricerca Corrente 2026 to the Candiolo Cancer Institute,FPO-IRCCS"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["2021 EmaGen"],"award-info":[{"award-number":["2021 EmaGen"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["2022 CARESS"],"award-info":[{"award-number":["2022 CARESS"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["Ricerca Finalizata 2021,ID RF-2021-12372851"],"award-info":[{"award-number":["Ricerca Finalizata 2021,ID RF-2021-12372851"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"EC | Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["754923 COLOSSUS"],"award-info":[{"award-number":["754923 COLOSSUS"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EMBO Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Molecular therapies targeting the EGFR\/MAPK pathway have improved outcomes in colorectal cancer (CRC), yet acquired resistance remains a major clinical challenge. Oncogenic signaling can activate stress response pathways that sustain tumor survival under therapeutic pressure. Among these, the DNA damage response (DDR) maintains genomic integrity and may represent a targetable vulnerability in resistant tumors. To investigate this, we developed a preclinical platform of CRC models with acquired resistance to anti-EGFR agents (\u201cARes platform\u201d). A targeted pharmacological screen of DDR inhibitors identified WEE1 kinase as a leading therapeutic candidate. Validation in xenograft models and patient-derived organoids confirmed that anti-EGFR-resistant CRCs retained, and in some cases increased, sensitivity to WEE1 inhibition. Mechanistically, resistant cells exhibited elevated DNA damage, heightened replication stress, and accelerated mitotic entry, culminating in cell death upon WEE1 blockade. These findings establish WEE1 as a promising therapeutic target in CRC with acquired resistance to EGFR inhibition and support the clinical evaluation of WEE1 inhibitors, alone or combined with DNA-damaging agents, for patients progressing on anti-EGFR\u2013based therapies.<\/jats:p>","DOI":"10.1038\/s44321-026-00434-4","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T09:03:50Z","timestamp":1779181430000},"page":"2322-2359","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["WEE1 kinase inhibition to overcome acquired resistance to targeted therapies in colorectal cancer"],"prefix":"10.1038","volume":"18","author":[{"given":"Kristi","family":"Buzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Bizzozero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilena","family":"Lentini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alena","family":"Opattova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Hern\u00e1ndez-Su\u00e1rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Chiabotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0787-9527","authenticated-orcid":false,"given":"Clelia","family":"Nistic\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5217-8201","authenticated-orcid":false,"given":"Giada","family":"De Lazzari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia","family":"R Zanella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaia","family":"Grasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Mariella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Durinikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8054-1402","authenticated-orcid":false,"given":"Michael","family":"Linnebacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Sartore-Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Siena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6379-3365","authenticated-orcid":false,"given":"Livio","family":"Trusolino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Bardelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1318-2494","authenticated-orcid":false,"given":"Sabrina","family":"Arena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"key":"434_CR1","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1158\/2159-8290.CD-20-0187","volume":"10","author":"V Amodio","year":"2020","unstructured":"Amodio V, Yaeger R, Arcella P, Cancelliere C, Lamba S, Lorenzato A, Arena S, Montone M, Mussolin B, Bian Y et al (2020) EGFR blockade reverts resistance to KRAS. Cancer Discov 10:1129\u20131139","journal-title":"Cancer Discov"},{"key":"434_CR2","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1158\/1078-0432.CCR-14-2821","volume":"21","author":"S Arena","year":"2015","unstructured":"Arena S, Bellosillo B, Siravegna G, Mart\u00ednez A, Ca\u00f1adas I, Lazzari L, Ferruz N, Russo M, Misale S, Gonz\u00e1lez I et al (2015) Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer. Clin Cancer Res 21:2157\u20132166","journal-title":"Clin Cancer Res"},{"key":"434_CR3","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1158\/1078-0432.CCR-19-2409","volume":"26","author":"S Arena","year":"2020","unstructured":"Arena S, Corti G, Durinikova E, Montone M, Reilly NM, Russo M, Lorenzato A, Arcella P, Lazzari L, Rospo G et al (2020) A subset of colorectal cancers with cross-sensitivity to olaparib and oxaliplatin. Clin Cancer Res 26:1372\u20131384","journal-title":"Clin Cancer Res"},{"key":"434_CR4","doi-asserted-by":"publisher","first-page":"324ra314","DOI":"10.1126\/scitranslmed.aad5640","volume":"8","author":"S Arena","year":"2016","unstructured":"Arena S, Siravegna G, Mussolin B, Kearns JD, Wolf BB, Misale S, Lazzari L, Bertotti A, Trusolino L, Adjei AA et al (2016) MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations. Sci Transl Med 8:324ra314","journal-title":"Sci Transl Med"},{"key":"434_CR5","doi-asserted-by":"publisher","first-page":"3515","DOI":"10.1200\/jco.2014.32.15_suppl.3515","volume":"32","author":"JC Bendell","year":"2014","unstructured":"Bendell JC, Atreya CE, Andr\u00e9 T, Tabernero J, Gordon MS, Bernards R, Cutsem EV, Tejpar S, Sidhu R, Go WY et al (2014) Efficacy and tolerability in an open-label phase I\/II study of MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in combination in patients (pts) with BRAF V600E mutated colorectal cancer (CRC). J Clin Oncol 32:3515","journal-title":"J Clin Oncol"},{"key":"434_CR6","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/nature11935","volume":"494","author":"RA Burrell","year":"2013","unstructured":"Burrell RA, McClelland SE, Endesfelder D, Groth P, Weller MC, Shaikh N, Domingo E, Kanu N, Dewhurst SM, Gronroos E et al (2013) Replication stress links structural and numerical cancer chromosomal instability. Nature 494:492\u2013496","journal-title":"Nature"},{"key":"434_CR7","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","volume":"34","author":"A Cervantes","year":"2023","unstructured":"Cervantes A, Adam R, Rosell\u00f3 S, Arnold D, Normanno N, Ta\u00efeb J, Seligmann J, De Baere T, Osterlund P, Yoshino T et al (2023) Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 34:10\u201332","journal-title":"Ann Oncol"},{"key":"434_CR8","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1038\/s41596-022-00754-y","volume":"18","author":"A Collins","year":"2023","unstructured":"Collins A, M\u00f8ller P, Gajski G, Vodenkov\u00e1 S, Abdulwahed A, Anderson D, Bankoglu EE, Bonassi S, Boutet-Robinet E, Brunborg G et al (2023) Measuring DNA modifications with the comet assay: a compendium of protocols. Nat Protoc 18:929\u2013989","journal-title":"Nat Protoc"},{"key":"434_CR9","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1016\/j.molcel.2021.07.015","volume":"81","author":"K Cong","year":"2021","unstructured":"Cong K, Peng M, Kousholt AN, Lee WTC, Lee S, Nayak S, Krais J, VanderVere-Carozza PS, Pawelczak KS, Calvo J et al (2021) Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency. Mol Cell 81:3227","journal-title":"Mol Cell"},{"key":"434_CR10","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1200\/JCO.19.00730","volume":"37","author":"KC Cuneo","year":"2019","unstructured":"Cuneo KC, Morgan MA, Sahai V, Schipper MJ, Parsels LA, Parsels JD, Devasia T, Al-Hawaray M, Cho CS, Nathan H et al (2019) Dose escalation trial of the Wee1 inhibitor adavosertib (AZD1775) in combination with gemcitabine and radiation for patients with locally advanced pancreatic cancer. J Clin Oncol 37:2643\u20132650","journal-title":"J Clin Oncol"},{"key":"434_CR11","doi-asserted-by":"crossref","unstructured":"Di Nicolantonio F, Vitiello PP, Marsoni S, Siena S, Tabernero J, Trusolino L, Bernards R, Bardelli A (2021) Precision oncology in metastatic colorectal cancer\u2014from biology to medicine. Nat Rev Clin Oncol 18:506\u2013525","DOI":"10.1038\/s41571-021-00495-z"},{"key":"434_CR12","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1158\/2159-8290.CD-23-0216","volume":"14","author":"MH Dias","year":"2024","unstructured":"Dias MH, Friskes A, Wang S, Fernandes Neto JM, van Gemert F, Mourragui S, Papagianni C, Kuiken HJ, Mainardi S, Alvarez-Villanueva D et al (2024) Paradoxical activation of oncogenic signaling as a cancer treatment strategy. Cancer Discov 14:1276\u20131301","journal-title":"Cancer Discov"},{"key":"434_CR13","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.devcel.2017.02.015","volume":"40","author":"H Duda","year":"2017","unstructured":"Duda H, Arter M, Gloggnitzer J, Teloni F, Wild P, Blanco MG, Altmeyer M, Matos J (2017) A mechanism for controlled breakage of under-replicated chromosomes during mitosis. Dev Cell 40:421\u2013422","journal-title":"Dev Cell"},{"key":"434_CR14","doi-asserted-by":"publisher","first-page":"3874","DOI":"10.1158\/1078-0432.CCR-22-0875","volume":"28","author":"E Durinikova","year":"2022","unstructured":"Durinikova E, Reilly NM, Buzo K, Mariella E, Chil\u00e0 R, Lorenzato A, Dias JML, Grasso G, Pisati F, Lamba S et al (2022) Targeting the DNA damage response pathways and replication stress in colorectal cancer. Clin Cancer Res 28:3874\u20133889","journal-title":"Clin Cancer Res"},{"key":"434_CR15","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1200\/JCO.22.00830","volume":"41","author":"S Fu","year":"2023","unstructured":"Fu S, Yao S, Yuan Y, Previs RA, Elias AD, Carvajal RD, George TJ, Yu L, Westin SN, Xing Y et al (2023) Multicenter phase II trial of the WEE1 inhibitor adavosertib in refractory solid tumors harboring. J Clin Oncol 41:1725\u20131734","journal-title":"J Clin Oncol"},{"key":"434_CR16","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41568-022-00535-5","volume":"23","author":"FJ Groelly","year":"2023","unstructured":"Groelly FJ, Fawkes M, Dagg RA, Blackford AN, Tarsounas M (2023) Targeting DNA damage response pathways in cancer. Nat Rev Cancer 23:78\u201394","journal-title":"Nat Rev Cancer"},{"key":"434_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-66018-5","volume":"10","author":"DH Ha","year":"2020","unstructured":"Ha DH, Min A, Kim S, Jang H, Kim SH, Kim HJ, Ryu HS, Ku JL, Lee KH, Im SA (2020) Antitumor effect of a WEE1 inhibitor and potentiation of olaparib sensitivity by DNA damage response modulation in triple-negative breast cancer. Sci Rep 10:9930","journal-title":"Sci Rep"},{"key":"434_CR18","doi-asserted-by":"crossref","unstructured":"Hossain MS, Karuniawati H, Jairoun AA, Urbi Z, Ooi J, John A, Lim YC, Kibria KMK, Mohiuddin AKM, Ming LC et al (2022) Colorectal cancer: a review of carcinogenesis, global epidemiology, current challenges, risk factors, preventive and treatment strategies. Cancers 14:1732","DOI":"10.3390\/cancers14071732"},{"key":"434_CR19","doi-asserted-by":"publisher","first-page":"W739","DOI":"10.1093\/nar\/gkac382","volume":"50","author":"A Ianevski","year":"2022","unstructured":"Ianevski A, Giri AK, Aittokallio T (2022) SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples. Nucleic Acids Res 50:W739\u2013W743","journal-title":"Nucleic Acids Res"},{"key":"434_CR20","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1158\/2159-8290.CD-17-1461","volume":"8","author":"P Kotsantis","year":"2018","unstructured":"Kotsantis P, Petermann E, Boulton SJ (2018) Mechanisms of oncogene-induced replication stress: jigsaw falling into place. Cancer Discov 8:537\u2013555","journal-title":"Cancer Discov"},{"key":"434_CR21","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1093\/nar\/gkv948","volume":"44","author":"HB Kramer","year":"2016","unstructured":"Kramer HB, Lai CF, Patel H, Periyasamy M, Lin ML, Feller SM, Fuller-Pace FV, Meek DW, Ali S, Buluwela L (2016) LRH-1 drives colon cancer cell growth by repressing the expression of the CDKN1A gene in a p53-dependent manner. Nucleic Acids Res 44:582\u2013594","journal-title":"Nucleic Acids Res"},{"key":"434_CR22","doi-asserted-by":"publisher","first-page":"4354","DOI":"10.1200\/JCO.2016.67.5942","volume":"34","author":"S Leijen","year":"2016","unstructured":"Leijen S, van Geel RM, Sonke GS, de Jong D, Rosenberg EH, Marchetti S, Pluim D, van Werkhoven E, Rose S, Lee MA et al (2016) Phase II study of WEE1 inhibitor AZD1775 plus carboplatin in patients with TP53-mutated ovarian cancer refractory or resistant to first-line therapy within 3 months. J Clin Oncol 34:4354\u20134361","journal-title":"J Clin Oncol"},{"key":"434_CR23","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S0140-6736(20)32554-X","volume":"397","author":"S Lheureux","year":"2021","unstructured":"Lheureux S, Cristea MC, Bruce JP, Garg S, Cabanero M, Mantia-Smaldone G, Olawaiye AB, Ellard SL, Weberpals JI, Wahner Hendrickson AE et al (2021) Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet 397:281\u2013292","journal-title":"Lancet"},{"key":"434_CR24","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1200\/JCO.20.03167","volume":"39","author":"JF Liu","year":"2021","unstructured":"Liu JF, Xiong N, Campos SM, Wright AA, Krasner C, Schumer S, Horowitz N, Veneris J, Tayob N, Morrissey S et al (2021) Phase II study of the WEE1 inhibitor adavosertib in recurrent uterine serous carcinoma. J Clin Oncol 39:1531\u20131539","journal-title":"J Clin Oncol"},{"key":"434_CR25","doi-asserted-by":"crossref","unstructured":"Lorenzato A, Magr\u00ec A, Matafora V, Audrito V, Arcella P, Lazzari L, Montone M, Lamba S, Deaglio S, Siena S et al (2020) Vitamin C restricts the emergence of acquired resistance to EGFR-targeted therapies in colorectal cancer. Cancers 12:685","DOI":"10.3390\/cancers12030685"},{"key":"434_CR26","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.annonc.2020.05.027","volume":"31","author":"G Mauri","year":"2020","unstructured":"Mauri G, Arena S, Siena S, Bardelli A, Sartore-Bianchi A (2020) The DNA damage response pathway as a land of therapeutic opportunities for colorectal cancer. Ann Oncol 31:1135\u20131147","journal-title":"Ann Oncol"},{"key":"434_CR27","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1158\/1078-0432.CCR-17-3796","volume":"24","author":"E M\u00e9ndez","year":"2018","unstructured":"M\u00e9ndez E, Rodriguez CP, Kao MC, Raju S, Diab A, Harbison RA, Konnick EQ, Mugundu GM, Santana-Davila R, Martins R et al (2018) A phase I clinical trial of AZD1775 in combination with neoadjuvant weekly docetaxel and cisplatin before definitive therapy in head and neck squamous cell carcinoma. Clin Cancer Res 24:2740\u20132748","journal-title":"Clin Cancer Res"},{"key":"434_CR28","doi-asserted-by":"publisher","first-page":"224ra226","DOI":"10.1126\/scitranslmed.3007947","volume":"6","author":"S Misale","year":"2014","unstructured":"Misale S, Arena S, Lamba S, Siravegna G, Lallo A, Hobor S, Russo M, Buscarino M, Lazzari L, Sartore-Bianchi A et al (2014a) Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer. Sci Transl Med 6:224ra226","journal-title":"Sci Transl Med"},{"key":"434_CR29","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1158\/2159-8290.CD-14-0462","volume":"4","author":"S Misale","year":"2014","unstructured":"Misale S, Di Nicolantonio F, Sartore-Bianchi A, Siena S, Bardelli A (2014b) Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. Cancer Discov 4:1269\u20131280","journal-title":"Cancer Discov"},{"key":"434_CR30","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/nature11156","volume":"486","author":"S Misale","year":"2012","unstructured":"Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M, Siravegna G et al (2012) Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486:532\u2013536","journal-title":"Nature"},{"key":"434_CR31","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1158\/1078-0432.CCR-21-0158","volume":"28","author":"KN Moore","year":"2022","unstructured":"Moore KN, Chambers SK, Hamilton EP, Chen LM, Oza AM, Ghamande SA, Konecny GE, Plaxe SC, Spitz DL, Geenen JJJ et al (2022) Adavosertib with chemotherapy in patients with primary platinum-resistant ovarian, fallopian tube, or peritoneal cancer: an open-label, four-arm, phase II study. Clin Cancer Res 28:36\u201344","journal-title":"Clin Cancer Res"},{"key":"434_CR32","doi-asserted-by":"publisher","first-page":"4504","DOI":"10.1158\/0008-5472.CAN-16-0396","volume":"76","author":"D Oddo","year":"2016","unstructured":"Oddo D, Sennott EM, Barault L, Valtorta E, Arena S, Cassingena A, Filiciotto G, Marzolla G, Elez E, van Geel RM et al (2016) Molecular landscape of acquired resistance to targeted therapy combinations in BRAF-mutant colorectal cancer. Cancer Res 76:4504\u20134515","journal-title":"Cancer Res"},{"key":"434_CR33","doi-asserted-by":"crossref","unstructured":"Pissarra AJ, Abreu C, Mansinho A, Costa AL, D\u00e2maso S, Lobo-Martins S, Martins M, Costa L (2021) Landscape of current targeted therapies for advanced colorectal cancer. In Colorectal Cancer, Vannelli A (ed), London: IntechOpen, pp 123\u2013154","DOI":"10.5772\/intechopen.93978"},{"key":"434_CR34","doi-asserted-by":"publisher","first-page":"e20190138","DOI":"10.1590\/1678-4685-gmb-2019-0138","volume":"43","author":"LMF Primo","year":"2019","unstructured":"Primo LMF, Teixeira LK (2019) DNA replication stress: oncogenes in the spotlight. Genet Mol Biol 43:e20190138","journal-title":"Genet Mol Biol"},{"key":"434_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1398419","volume":"15","author":"A R\u00edos-Hoyo","year":"2024","unstructured":"R\u00edos-Hoyo A, Monzon\u00eds X, Vidal J, Linares J, Montagut C (2024) Unveiling acquired resistance to anti-EGFR therapies in colorectal cancer: a long and winding road. Front Pharm 15:1398419","journal-title":"Front Pharm"},{"key":"434_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.954430","volume":"12","author":"P Roering","year":"2022","unstructured":"Roering P, Siddiqui A, Heuser VD, Potdar S, Mikkonen P, Oikkonen J, Li Y, Pikkusaari S, Wennerberg K, Hynninen J et al (2022) Effects of Wee1 inhibitor adavosertib on patient-derived high-grade serous ovarian cancer cells are multiple and independent of homologous recombination status. Front Oncol 12:954430","journal-title":"Front Oncol"},{"key":"434_CR37","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1126\/science.aav4474","volume":"366","author":"M Russo","year":"2019","unstructured":"Russo M, Crisafulli G, Sogari A, Reilly NM, Arena S, Lamba S, Bartolini A, Amodio V, Magr\u00ec A, Novara L et al (2019) Adaptive mutability of colorectal cancers in response to targeted therapies. Science 366:1473\u20131480","journal-title":"Science"},{"key":"434_CR38","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2020-000911","volume":"5","author":"A Sartore-Bianchi","year":"2020","unstructured":"Sartore-Bianchi A, Lonardi S, Martino C, Fenocchio E, Tosi F, Ghezzi S, Leone F, Bergamo F, Zagonel V, Ciardiello F et al (2020) Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial. ESMO Open 5:e000911","journal-title":"ESMO Open"},{"key":"434_CR39","doi-asserted-by":"publisher","first-page":"3705","DOI":"10.1200\/JCO.21.01435","volume":"39","author":"JF Seligmann","year":"2021","unstructured":"Seligmann JF, Fisher DJ, Brown LC, Adams RA, Graham J, Quirke P, Richman SD, Butler R, Domingo E, Blake A et al (2021) Inhibition of WEE1 is effective in TP53- and RAS-mutant metastatic colorectal cancer: a randomized trial (FOCUS4-C) comparing adavosertib (AZD1775) with active monitoring. J Clin Oncol 39:3705\u20133715","journal-title":"J Clin Oncol"},{"key":"434_CR40","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A (2024) Cancer statistics, 2024. CA Cancer J Clin 74:12\u201349","journal-title":"CA Cancer J Clin"},{"key":"434_CR41","doi-asserted-by":"crossref","unstructured":"Thangaretnam K, Islam MO, Lv J, El-Rifai A, Perloff A, Soutto HL, Peng D, Chen Z (2025) WEE1 inhibition in cancer therapy: mechanisms, synergies, preclinical insights, and clinical trials. Crit Rev Oncol\/Hematol 211:104710","DOI":"10.1016\/j.critrevonc.2025.104710"},{"key":"434_CR42","first-page":"3499","volume":"18","author":"W Voigt","year":"1998","unstructured":"Voigt W, Matsui S, Yin MB, Burhans WC, Minderman H, Rustum YM (1998) Topoisomerase-I inhibitor SN-38 can induce DNA damage and chromosomal aberrations independent from DNA synthesis. Anticancer Res 18:3499\u20133505","journal-title":"Anticancer Res"},{"key":"434_CR43","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1158\/2159-8290.CD-22-0405","volume":"13","author":"R Yaeger","year":"2023","unstructured":"Yaeger R, Mezzadra R, Sinopoli J, Bian Y, Marasco M, Kaplun E, Gao Y, Zhao H, Paula ADC, Zhu Y et al (2023) Molecular characterization of acquired resistance to KRASG12C-EGFR inhibition in colorectal cancer. Cancer Discov 13:41\u201355","journal-title":"Cancer Discov"}],"container-title":["EMBO Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44321-026-00434-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1038\/s44321-026-00434-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44321-026-00434-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T06:32:50Z","timestamp":1781505170000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1038\/s44321-026-00434-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":43,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6,15]]}},"alternative-id":["434"],"URL":"https:\/\/doi.org\/10.1038\/s44321-026-00434-4","relation":{},"ISSN":["1757-4684"],"issn-type":[{"value":"1757-4684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]},"assertion":[{"value":"30 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S. Arena (SA) reports personal fees from MSD Italia and a patent (Italian patent application No. 102022000007535) outside the submitted work. A. Bardelli (AB) declares the following competing financial interests: receipt of grants\/research supports from Neophore; stock shareholder: Neophore, Kither Biotech; member of the SAB of Neophore. Livio Trusolino (LT) has received research grants from Menarini, Merck KGaA, Merus, Pfizer, Servier and Symphogen.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure and competing interests statement"}}]}}